CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+36.31%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$890M
AUM Growth
+$890M
(+35%)
Cap. Flow
+$90.2M
Cap. Flow
% of AUM
10.14%
Top 10 Holdings %
Top 10 Hldgs %
74.13%
Holding
34
New
2
Increased
15
Reduced
2
Closed
8
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$42.1M |
| 2 |
Akero Therapeutics
AKRO
|
$41.3M |
| 3 |
Vaxcyte
PCVX
|
$40.7M |
| 4 |
Merus
MRUS
|
$27.6M |
| 5 |
IDEAYA Biosciences
IDYA
|
$18.2M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$47.4M |
| 2 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$26.8M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$13.6M |
| 4 |
Immunovant
IMVT
|
$10.3M |
| 5 |
Avidity Biosciences
RNA
|
$9.07M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $105M | 11.84% |
4,000,000
+1,050,000
| +36% | +$27.6M |
|
|
2
Vera Therapeutics
VERA
$1.38B
| $87.5M | 9.83% |
5,450,000
+2,625,971
| +93% | +$42.1M |
|
|
3
Akero Therapeutics
AKRO
$3.74B
| $78.2M | 8.79% |
1,675,000
+885,000
| +112% | +$41.3M |
|
4
Xenon Pharmaceuticals
XENE
$2.98B
| $71M | 7.98% |
1,845,000
| – | – |
|
5
Cogent Biosciences
COGT
$1.69B
| $65.9M | 7.41% |
5,566,026
+793,605
| +17% | +$9.4M |
|
6
Viridian Therapeutics
VRDN
$1.5B
| $52.3M | 5.88% |
2,200,000
+10,341
| +0.5% | +$246K |
|
|
AMAM
7
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $52.3M | 5.87% |
3,175,000
-1,628,447
| -34% | -$26.8M |
|
|
8
Vaxcyte
PCVX
$4B
| $50.7M | 5.7% |
1,015,000
+815,000
| +408% | +$40.7M |
|
9
Nuvalent
NUVL
$5.52B
| $48.5M | 5.45% |
1,150,000
+75,000
| +7% | +$3.16M |
|
10
Enliven Therapeutics
ELVN
$1.2B
| $47.9M | 5.39% |
2,348,272
+616,907
| +36% | +$12.6M |
|
11
Cabaletta Bio
CABA
$133M
| $30.6M | 3.44% |
2,368,186
+533,186
| +29% | +$6.88M |
|
|
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
| $22.2M | 2.49% |
2,025,000
| – | – |
|
13
Arrowhead Research
ARWR
$3.05B
| $21.8M | 2.44% |
610,000
+35,000
| +6% | +$1.25M |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $21.4M | 2.41% |
631,665
+135,842
| +27% | +$4.61M |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $20.9M | 2.35% |
997,596
+143,712
| +17% | +$3.01M |
|
|
16
IDEAYA Biosciences
IDYA
$2.15B
| $18.2M | 2.05% |
+775,000
| New | +$18.2M |
|
|
17
Immunovant
IMVT
$2.56B
| $17.1M | 1.92% |
900,000
-540,999
| -38% | -$10.3M |
|
18
Adverum Biotechnologies
ADVM
$64.6M
| $15.9M | 1.79% |
10,000,000
+5,000,000
| +100% | +$7.95M |
|
19
Celcuity
CELC
$2.17B
| $15.9M | 1.78% |
1,444,141
+53,369
| +4% | +$586K |
|
20
Kura Oncology
KURA
$686M
| $14.8M | 1.66% |
1,400,000
+195,042
| +16% | +$2.06M |
|
|
ALPN
21
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $13.6M | 1.53% |
1,325,000
| – | – |
|
22
Day One Biopharmaceuticals
DAWN
$769M
| $8.83M | 0.99% |
739,661
| – | – |
|
|
THRD
23
DELISTED
Third Harmonic Bio
THRD
| $4.78M | 0.54% |
993,294
| – | – |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $2.81M | 0.32% |
312,553
| – | – |
|
25
Spyre Therapeutics
SYRE
$996M
| $1.31M | 0.15% |
+2,908,100
| New | +$1.31M |
|